28.03.2019, 23:49
Healthcare | Biotechnology | USA
SEEL nachbörslich 25% nach oben auf aktuell 3.68:
Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights
- First patient with Sanfilippo Syndrome expected to be dosed with Trehalose in an open-label phase IIb trial in 2Q 2019 –
- Plan to initiate phase I study with intranasal racemic ketamine in Suicidality-PTSD in the summer of 2019–
- Proof of concept for Target Engagement for peptide-based approach targeting the NACore in Parkinson’s Disease expected to begin in 2Q 2019 –
- Management to share archived webcast of interview with the TD Ameritrade Network –
...
https://finance.yahoo.com/news/seelos-th...00285.html
![[Bild: SEELc1dl1748.png]](https://finviz.com/publish/032819/SEELc1dl1748.png)
SEEL nachbörslich 25% nach oben auf aktuell 3.68:
Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights
- First patient with Sanfilippo Syndrome expected to be dosed with Trehalose in an open-label phase IIb trial in 2Q 2019 –
- Plan to initiate phase I study with intranasal racemic ketamine in Suicidality-PTSD in the summer of 2019–
- Proof of concept for Target Engagement for peptide-based approach targeting the NACore in Parkinson’s Disease expected to begin in 2Q 2019 –
- Management to share archived webcast of interview with the TD Ameritrade Network –
...
https://finance.yahoo.com/news/seelos-th...00285.html